Cencora’s Top Executive Makes Major Insider Stock Move

New insider activity at Cencora ( (COR) ) has taken place on January 22, 2026.

President & CEO Robert Mauch has sold 5,096 shares of Cencora stock in a recent transaction. The sale of these shares amounted to a total value of $1,807,704, signaling a notable insider move at the company.

Recent Updates on COR stock

Over the last 24 hours, the key development for Cencora has been Jefferies’ upgrade of the stock, driven by a reassessment of its risk profile and growth outlook rather than any single earnings event. The firm highlighted that major overhangs tied to Walgreens’ store closure program and potential U.S. government Most Favored Nation drug pricing changes have largely cleared, reducing regulatory and customer-concentration risk. With these issues fading, Jefferies now sees the broader pharmacy distribution sector, and Cencora in particular, benefiting from multi-year tailwinds that support stronger growth and justify valuation multiple expansion. The analyst expects Cencora to follow an accelerated growth path over the coming years, which underpins the more constructive view on the stock’s future performance and the associated upward revision to expectations, even though specific price levels and recommendations were not disclosed here.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Outperform.

The score is driven mainly by solid financial performance—especially strong cash flow generation—alongside supportive technical uptrend signals. This is moderated by a high valuation (elevated P/E and low yield) and balance-sheet leverage, while the latest earnings call was broadly positive due to raised guidance despite noted impairments and higher interest costs.

To see Spark’s full report on COR stock, click here.

More about Cencora

YTD Price Performance: 4.15%

Average Trading Volume: 1,417,302

Technical Sentiment Signal: Buy

Current Market Cap: $68.03B